コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 r lack of efficacy as determined by the Data Safety Monitoring Board.
2 reviewed frequently by a collective data and safety monitoring board.
3 on the recommendation of the unblinded Data Safety Monitoring Board.
4 ated by a clinical events committee and data safety monitoring board.
5 oratory, clinical events committee, and data safety monitoring board.
6 s stopped early for futility by the Data and Safety Monitoring Board.
7 min group due to recommendations by the data safety monitoring board.
8 d based on recommendations from the data and safety monitoring board.
9 im and final analysis by the masked Data and Safety Monitoring Board.
10 y and safety concerns identified by the Data Safety Monitoring Board.
11 tility on the recommendation of the data and safety monitoring board.
12 he basis of a recommendation by the data and safety monitoring board.
13 e retina specialist (M.A.Z.) on the Data and Safety Monitoring Board.
14 vessel dilation as assessed by the Data and Safety Monitoring Board.
15 early on the recommendation of the data and safety monitoring board.
16 y 2006 at the recommendation of the data and safety monitoring board.
17 rd interim analysis reviewed by the data and safety monitoring board.
18 2003, on the recommendation of the data and safety monitoring board.
19 ety reasons after the advice of the Data and Safety Monitoring Board.
20 uine group was stopped early by the data and safety monitoring board.
21 following the recommendation of the data and safety monitoring board.
22 ial was stopped for efficacy by the data and safety monitoring board 1 year after randomization was c
23 oversight of Steering Committee and Data and Safety Monitoring Board activities), whereas the CRO pro
26 ly at the advice of the independent data and safety monitoring board after a median follow-up of 2.2
27 after unanimous recommendation from the Data Safety Monitoring Board after enrolling 30 patients beca
29 The study was terminated by the data and safety monitoring board after randomization of 1331 pati
30 he recommendation of an independent data and safety monitoring board, after the interim analysis show
32 nt recruitment and participation in the data safety monitoring board and clinical coordinating center
33 re terminated early, 84 (88%) had a data and safety monitoring board, and 57 (59%) reported a prespec
34 on makers, institutional review boards, data safety monitoring boards, and confidentiality measures.
35 s stopped on April 15, 2013, when a data and safety monitoring board appointed by the National Instit
36 r each patient completed treatment, the data safety monitoring board approved respective dose escalat
37 by the sponsor and the independent data and safety monitoring board because of both a lack of effica
38 rial was prematurely stopped by the data and safety monitoring board because of safety concerns and a
40 e trial was stopped by the external data and safety monitoring board because the second preplanned in
41 trials and recommendation from the data and safety monitoring board, but were analysed as being in t
42 interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to v
43 of 156 of 265 planed patients, the data and safety monitoring board decided to hold the randomizatio
44 s after enrollment, the independent data and safety monitoring board detected an unanticipated imbala
45 domization of the last subject, the Data and Safety Monitoring Board determined that the primary rese
46 e basis of an interim analysis, the data and safety monitoring board determined that the study questi
48 interim analysis at 50% enrollment, the Data Safety Monitoring Board (DSMB) expressed concern that an
49 to this complexity, an Independent Data and Safety Monitoring Board (DSMB) is best suited to deal wi
54 4 weeks, upon recommendation of the data and safety monitoring board due to futility for efficacy at
56 ed as per the recommendation of the data and safety monitoring board for futility reasons after inclu
58 is study was reviewed by an independent data safety monitoring board for safety and efficacy after en
61 r an interim analysis by an independent data safety monitoring board indicated no discernible treatme
63 2003, on the recommendation of the data and safety monitoring board; mortality in these groups did n
64 minated early after the independent data and safety monitoring board noted an increased annualised re
65 rematurely by recommendation of the Data and Safety Monitoring Board on July 27, 2016, after 168 pati
66 ated early on the recommendation of its data safety monitoring board on the basis of slow accrual and
67 h bioanalysts who prepared data for the data safety monitoring board or generated pharmacokinetic or
68 early on the recommendation of the data and safety monitoring board owing to overwhelming efficacy.
69 e trial was terminated early by the data and safety monitoring board owing to safety and outcome conc
70 early on the recommendation of the data and safety monitoring board owing to the finding of reduced
71 early, on the recommendation of the data and safety monitoring board, owing to a low likelihood of be
72 ta monitoring committees (DMCs), or data and safety monitoring boards, protect clinical trial partici
73 a recommendation by an independent data and safety monitoring board, randomisation was stopped and i
74 ility boundary was crossed, and the data and safety monitoring board recommend study closure, having
75 ta from the first 443 patients, the data and safety monitoring board recommended discontinuation of e
77 he basis of these observations, the data and safety monitoring board recommended early discontinuatio
80 he basis of evidence of futility, a data and safety monitoring board recommended early termination af
83 bjects worsening on sildenafil, the data and safety monitoring board recommended early termination of
90 o deaths; P = 0.005) an independent Data and Safety Monitoring Board recommended stopping the study a
92 mean of 5.2 years of follow-up, the data and safety monitoring board recommended stopping the trial o
93 periority boundary (P = .0061), the data and safety monitoring board recommended study termination on
94 (planned duration, 8.5 years), the data and safety monitoring board recommended terminating the estr
95 y end point events, the independent data and safety monitoring board recommended termination of the t
97 cted total number), the independent data and safety monitoring board recommended termination of the t
98 o August 9, 2019, at which time the data and safety monitoring board recommended that patients be ass
99 ter a planned interim analysis, the data and safety monitoring board recommended that the studies be
101 At the third interim analysis, the data and safety monitoring board recommended that the trial halt
106 ic of coronavirus disease 2019, the data and safety monitoring board requested an unplanned interim a
108 rual was halted on the basis of the data and safety monitoring board review of a futility analysis.
109 d, the patient enrollment was stopped (after safety monitoring board review) because of excess reject
110 ndertaken during the studies, and a data and safety monitoring board reviewed all the data during and
111 llment of the first 197 patients, a data and safety monitoring board reviewed potential drug-related
112 The study was stopped early per the data and safety monitoring board's recommendation because of grea
113 titutional review boards [IRBs] and data and safety monitoring boards) should consult with or include
114 ed interim review by an independent data and safety monitoring board showed significant differences i
118 5 patients were enrolled before the data and safety monitoring board stopped the trial because of the
119 b 6, 2017, to Jan 9, 2018, when the data and safety monitoring board stopped the trial on the basis o
121 itoring conducted by an independent data and safety monitoring board, study enrollment was terminated
122 standard care and the conclusion of the data safety monitoring board that further recruitment would n
125 r treatment; this was judged by the data and safety monitoring board to be possibly related to treatm
126 ls, laboratory assays, and a single data and safety monitoring board to oversee the various studies.
128 n therapy, prompted the independent data and safety monitoring board to recommend termination of the
129 ors, data analysts, and the independent data safety monitoring board were all blinded to group alloca
130 topped at the recommendation of the data and safety monitoring board when prespecified criteria for f
131 terminated early by an independent data and safety monitoring board when statistically significant r
132 t the recommendation of an external Data and Safety Monitoring Board, which noted a negative trend in